Home Stocks MGNX MacroGenics Inc (NASDAQ: MGNX) Healthcare · Biotechnology
$1.97 −0.08 (−3.90%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. MGNX fell 3.90% in the Nov 18 session to $1.97, which is 59.5% below its 52-week high of $4.86. Short interest is 8.75% of float with a 1.70% borrow fee. Two active firms cover the stock as of Nov 19, 2026; two active firms with targets average $8.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Relative valuation Lower multiples than peers P/S 0.9× vs peer median 13.9×
Momentum Neutral RSI (14) 34.5 (overbought above 70, oversold below 30)
Short interest 8.8% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $2.02 Nov 18, 2026 session
Previous close $2.05 Nov 17, 2026 close
Day range $1.94 – $2.06 Nov 18, 2026 session
52-week range $1.33 – $4.86 Through Nov 18, 2026
Volume 720.20K Nov 18, 2026 session
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $152.88M
P/E (TTM) 25.3
Forward P/E —
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 1.34
Price history MGNX · nasdaq · USD
Last completed session: Nov 18, 2026
Split-adjusted · volume in shares
November 2026 · 13 completed sessions Date Open High Low Close Change Volume Nov 18 2.02 2.055 1.935 1.97 −0.08−3.902439% 704,173 Open 2.02 High 2.055 Low 1.935 Nov 17 2.13 2.1799 2.02 2.05 −0.12−5.529954% 572,902 Open 2.13 High 2.1799 Low 2.02 Nov 16 2.22 2.25 1.9302 2.17 −0.03−1.363636% 886,958 Open 2.22 High 2.25 Low 1.9302 Nov 13 2.26 2.27 2.05 2.20 −0.09−3.930131% 997,842 Open 2.26 High 2.27 Low 2.05 Nov 12 2.31 2.43 2.24 2.29 −0.03−1.293103% 894,630 Open 2.31 High 2.43 Low 2.24 Nov 11 2.42 2.42 2.32 2.32 −0.10−4.132231% 451,230 Open 2.42 High 2.42 Low 2.32 Nov 10 2.31 2.43 2.31 2.42 +0.08+3.418803% 468,035 Open 2.31 High 2.43 Low 2.31 Nov 9 2.36 2.49 2.33 2.34 +0.01+0.429185% 953,368 Open 2.36 High 2.49 Low 2.33 Nov 6 2.26 2.445 2.25 2.33 +0.11+4.954955% 695,812 Open 2.26 High 2.445 Low 2.25 Nov 5 2.30 2.3336 2.205 2.22 −0.09−3.896104% 1,299,085 Open 2.30 High 2.3336 Low 2.205 Nov 4 2.39 2.46 2.23 2.31 −0.02−0.858369% 919,162 Open 2.39 High 2.46 Low 2.23 Nov 3 2.36 2.49 2.2601 2.33 0.000.00% 409,139 Open 2.36 High 2.49 Low 2.2601 Nov 2 2.41 2.535 2.32 2.33 −0.07−2.916667% 766,121 Open 2.41 High 2.535 Low 2.32
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
How MGNX compares with its industry Against 592 other US-listed Biotechnology stocks
Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%
Strongest pointsLatest-quarter year-over-year sales growth was 378%, higher than 93% of 592 peers.Peer median 0.0% · As of Nov 17, 2026 One-year return was 30.5%, higher than 80% of 522 peers.Peer median −28.4% · As of Nov 17, 2026 Points of cautionOne-month return was -43.6%, with only 11% of 567 peers reporting a lower value.Peer median −13.8% · As of Nov 17, 2026 Trailing-year net margin was -8.3%, with only 17% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026 Trailing-year return on equity was -225.8%, with only 18% of 554 peers reporting a lower value.Peer median −67.8% · As of Nov 17, 2026 Valuation Lower multiples than peers
Metric MGNX Peer median
Profitability Profitability metrics are lower than most peers.
Metric MGNX Peer median
Gross margin −0.7% 78.6%
Not ranked: only 246 of 592 peers report it
Operating margin −42.2% 0.0%
Higher than 19% of 442 peers
Net margin −8.3% 0.0%
Higher than 17% of 583 peers
Return on equity −225.9% −67.8%
Higher than 18% of 554 peers
Growth Growth metrics are higher than most peers.
Metric MGNX Peer median
Quarterly sales growth, year over year 378.0% 0.0%
Top 10% of peers Higher than 93% of 592 peers
5-year sales growth rate 7.3% 11.6%
Not ranked: only 139 of 592 peers report it
Balance sheet Balance sheet metrics are lower than most peers.
Metric MGNX Peer median
Momentum Returns are mixed versus peers.
Metric MGNX Peer median
1-year return +30.5% −28.4%
Higher than 80% of 522 peers
6-month return −55.8% −26.6%
Higher than 22% of 545 peers
3-month return −51.6% −29.4%
Higher than 22% of 558 peers
How to read this The dot marks where MGNX ranks among its peers on each metric, from lowest (left) to highest (right). The tick in the middle marks the peer median.
Green marks a rank in the top 10% of peers, amber the bottom 10%. Valuation and balance-sheet metrics stay neutral because a high rank there is not better or worse.
A metric is ranked only when enough peers report it. Peers exclude this company. Percentages count peers with a strictly lower value; equal values do not count.
Lowest Median Highest
Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 13, 2026
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
2 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 2 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $8.50
High $11.00
As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −1.50 −1.00 −0.50 0.00 0.50 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.13 −$0.32 —
Q2 2026 $0.26 $0.31 —
Q1 2026 −$0.55 −$0.58 —
Annual 2025 −$0.27 −$1.18 —
Q3 2025 — $0.27 —
Q2 2025 — −$0.57 —
Q1 2025 — −$0.65 —
Annual 2024 −$0.59 −$1.07 —
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Aug 19, 2026 Insider sell Peters Jeffrey Stuart Sell $129.1K Form 4 All smart-money activity →
News and press releases Year All 2026 2024 Nov 12, 2026, 4:01 PM ET Nov 5, 2026, 4:05 PM ET Nov 3, 2026, 4:05 PM ET Oct 26, 2026, 7:06 AM ET Oct 23, 2026, 9:15 AM ET Oct 15, 2026, 4:05 PM ET Sep 9, 2026, 4:05 PM ET Aug 13, 2026, 4:05 PM ET Aug 11, 2026, 4:05 PM ET Jul 23, 2026, 4:01 PM ET All MGNX news → Company profile MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic
CEO Mr. Eric Blasius Risser
Headquarters Rockville, MD, United States
Employees 293
IPO date Oct 10, 2013
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Insufficient coverage
0 Strong Buy
2 Buy
0 Neutral
0 Sell
0 Strong Sell
Based on 2 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $6.00
Average $8.50
High $11.00
As of Nov 19, 2026 across 2 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −1.50 −1.00 −0.50 0.00 0.50 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.13 −$0.32 —
Q2 2026 $0.26 $0.31 —
Q1 2026 −$0.55 −$0.58 —
Annual 2025 −$0.27 −$1.18 —
Q3 2025 — $0.27 —
Q2 2025 — −$0.57 —
Q1 2025 — −$0.65 —
Annual 2024 −$0.59 −$1.07 —
Company profile MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic
CEO Mr. Eric Blasius Risser
Headquarters Rockville, MD, United States
Employees 293
IPO date Oct 10, 2013
Sector Healthcare
Industry Biotechnology